Episode: 51 - Setting the Right Strategy to Drive Engineering Parameters for Solid Tumor-Targeting T Cell-Engagers

In this special episode of The Chain, G. Jonah Rainey, Senior Director of Protein Engineering at Eli Lilly and Company, hosts a panel at PEGS 2023 to discuss strategies to engineer parameters for solid tumor-targeting T-cell-engagers. Guests Stephen J. Demarest from Tentarix Biotherapeutics, Michelle Morrow from F-Star Therapeutics, Inc., and Dario Neri from Philogen provide their insights and experiences on navigating challenges, researching treatments, and the positives and negatives of certain targeting strategies. They also answer questions from the audience and share their perspectives on the future of tumor-targeting and what technology can do to help with developing effective cures. Links from this episode:  PEGS Boston Conference & Expo Engineering Bispecific Antibodies Eli Lilly and CompanyTentatrix Biotherapeutics   F-Star Therapeutics, Inc. Philogen